BGBurkhard Gess

Burkhard Gess

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Burkhard Gess has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sodium‐dependent Vitamin C transporter 2 deficiency impairs myelination and remyelination after injury: Roles of collagen and demethylation

    by Dominik Röhr, Hartmut Halfter, Jörg B. Schulz, Peter Young, Burkhard Gess

    Peripheral nerve myelination involves rapid production of tightly bound lipid layers requiring cholesterol biosynthesis and myelin protein expression, but also a collagen‐containing extracellular matrix providing mechanical stability. In previous studies, we showed a function of ascorbic acid in peripheral nerve myelination and extracellular matrix formation in adult mice. Here, we sought the mechanism of action of ascorbic acid in peripheral nerve myelination using different paradigms of myelination in vivo and in vitro. We found impaired myelination and reduced collagen expression in Sodium‐dependent Vitamin C Transporter 2 heterozygous mice (SVCT2+/‐) during peripheral nerve development and after peripheral nerve injury. In dorsal root ganglion (DRG) explant cultures, hypo‐myelination could be rescued by precoating with different collagen types. The activity of the ascorbic acid‐dependent demethylating Ten‐eleven‐translocation (Tet) enzymes was reduced in ascorbic acid deprived and SVCT2+/‐ DRG cultures. Further, in ascorbic acid‐deprived DRG cultures, methylation of a CpG island in the collagen alpha1 (IV) and alpha2 (IV) bidirectional promoter region was increased compared to wild‐type and ascorbic acid treated controls. Taken together, these results provide further evidence for the function of ascorbic acid in myelination and extracellular matrix formation in peripheral nerves and suggest a putative molecular mechanism of ascorbic acid function in Tet‐dependent demethylation of collagen promoters.


  • Caveolin-1–mediated internalization of the vitamin C transporter SVCT2 in microglia triggers an inflammatory phenotype

    by Camila C. Portugal, Renato Socodato, Teresa Canedo, Cátia M. Silva, Tânia Martins, Vivian S. M. Coreixas, Erick C. Loiola, Burkhard Gess, Dominik Röhr, Ana R. Santiago, et al.

    Vitamin C is essential for the development and function of the central nervous system (CNS). The plasma membrane sodium–vitamin C cotransporter 2 (SVCT2) is the primary mediator of vitamin C uptake in neurons. SVCT2 specifically transports ascorbate, the reduced form of vitamin C, which acts as a reducing agent. We demonstrated that ascorbate uptake through SVCT2 was critical for the homeostasis of microglia, the resident myeloid cells of the CNS that are essential for proper functioning of the nervous tissue. We found that depletion of SVCT2 from the plasma membrane triggered a proinflammatory phenotype in microglia and resulted in microglia activation. Src-mediated phosphorylation of caveolin-1 on Tyr14 in microglia induced the internalization of SVCT2. Ascorbate treatment, SVCT2 overexpression, or blocking SVCT2 internalization prevented the activation of microglia. Overall, our work demonstrates the importance of the ascorbate transport system for microglial homeostasis and hints that dysregulation of ascorbate transport might play a role in neurological disorders.


  • Open Access

    Erratum to: CMTX1 patients’ cells present genomic instability corrected by CamKII inhibitors

    by Saleh Mones, Burkhard Gess, Benoit Bordignon, Alexandre Altié, Peter Young, Frederic Bihel, Marc Fraterno, Franck Peiretti, Michel Fontes


  • Ascorbic acid for the treatment of Charcot-Marie-Tooth disease

    by Burkhard Gess, Jonathan Baets, Peter De Jonghe, Mary M Reilly, Davide Pareyson, Peter Young

    Background Charcot‐Marie‐Tooth disease (CMT) comprises a large group of different forms of hereditary motor and sensory neuropathy. The molecular basis of several CMT subtypes has been clarified during the last 20 years. Since slowly progressive muscle weakness and sensory disturbances are the main features of these syndromes, treatments aim to improve motor impairment and sensory disturbances to improve abilities. Pharmacological treatment trials in CMT are rare. This review was derived from a Cochrane review, Treatment for Charcot Marie Tooth disease, which will be updated via this review and a forthcoming title, Treatments other than ascorbic acid for Charcot‐Marie‐Tooth disease. Objectives To assess the effects of ascorbic acid (vitamin C) treatment for CMT. Search methods On 21 September 2015, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS for randomised controlled trials (RCTs) of treatment for CMT. We also checked clinical trials registries for ongoing studies. Selection criteria We included RCTs and quasi‐RCTs of any ascorbic acid treatment for people with CMT. Where a study aimed to evaluate the treatment of general neuromuscular symptoms of people with peripheral neuropathy including CMT, we included the study if we were able to identify the effect of treatment in the CMT group. We did not include observational studies or case reports of ascorbic acid treatment in people with CMT. Data collection and analysis Two review authors (BG and JB) independently extracted the data and assessed study quality. Main results Six RCTs compared the effect of oral ascorbic acid (1 to 4 grams) and placebo treatment in CMT1A. In five trials involving adults with CMT1A, a total of 622 participants received ascorbic acid or placebo. Trials were largely at low risk of bias. There is high‐quality evidence that ascorbic acid does not improve the course of CMT1A in adults as measured by the CMT neuropathy score (0 to 36 scale) at 12 months (mean difference (MD) ‐0.37; 95% confidence intervals (CI) ‐0.83 to 0.09; five studies; N = 533), or at 24 months (MD ‐0.21; 95% CI ‐0.81 to 0.39; three studies; N = 388). Ascorbic acid treatment showed a positive effect on the nine‐hole peg test versus placebo (MD ‐1.16 seconds; 95% CI ‐1.96 to ‐0.37), but the clinical significance of this result is probably small. Meta‐analyses of other secondary outcome parameters showed no relevant benefit of ascorbic acid. In one trial, 80 children with CMT1A received ascorbic acid or placebo. The trial showed no clinical benefit of ascorbic acid treatment. Adverse effects did not differ in their nature or abundance between ascorbic acid and placebo. Authors' conclusions High‐quality evidence indicates that ascorbic acid does not improve the course of CMT1A in adults in terms of the outcome parameters used. According to low‐quality evidence, ascorbic acid does not improve the course of CMT1A in children. However, CMT1A is slowly progressive and the outcome parameters show only small change over time. Longer study durations should be considered, and outcome parameters more sensitive to change over time should be designed and validated for future studies.


  • Open Access

    CMTX1 patients’ cells present genomic instability corrected by CamKII inhibitors

    by Mones Saleh, Gess Burkhardt, Bordignon Benoit, Altié Alexandre, Young Peter, Bihel Frederic, Fraterno Marc, Peiretti Franck, Fontes Michel

    We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients. We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instabilty, connexon activity, and potential correction by CamKII inhibitors. The phenotypic analysis of these cells confirmed strong similarities between the GJB1 transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors. Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.


  • Genetik der Neuropathien

    by B. Gess, A. Schirmacher, P. Young